Allergan (AGN) announced that it has reached an agreement to acquire privately held ForSight VISION5 for $95M in upfront cash plus an undisclosed launch milestone payment related to its lead development program, a peri-ocular ring designed for extended drug delivery and lowering elevated intraocular pressure (IOP) in patients with glaucoma. ForSight's lead candidate, called the Bimatoprost Ring, is a non-invasive product that rests on the surface of the eye under the eyelid. It can be inserted by an optometrist as well as an ophthalmologist. Over a period of months, it slowly releases the drug bimatoprost (marketed in an eye drop formulation as LUMIGAN by Allergan) to lower IOP.